Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

BRIDGE-AD reveals Alzheimer's disease effectors through interpretable large-scale omics integration

Created on 21 Sep 2026

Authors

Cerneckis, J., Baltusyte, G., Convey, H., Sun, G., Abela, Z. C. E., Ramirez, M., Wang, D., Sun, G., Zhou, T., Spring, D., Saeb-Parsy, K., Han, N., Shi, Y.

Abstract

The growing landscape of Alzheimer's disease (AD) datasets creates opportunities to integrate heterogeneous evidence and systematically discover disease effectors. We present BRIDGE-AD, an interpretable network medicine framework that transforms multimodal data into a unified, disease-specific gene representation for AD effector prioritisation. We integrated more than 30 datasets and curated resources spanning omics, functional, genetic and prior disease knowledge layers. BRIDGE-AD outperformed recently published pretrained and modality-specific gene embeddings in recovering AD-associated genes and produced a genome-wide resource of candidate AD effectors. Established and newly prioritised effectors formed 19 functional clusters, revealing a global molecular landscape of AD biology. BRIDGE-AD supported an SPP1-centred cross-compartment hypothesis and nominated SCARB2, a poorly characterised candidate, for functional validation. SCARB2 rewired lysosomal, lipid-handling and autophagic programmes in microglia, whereas disrupted SCARB2 glycosylation in AD implicated altered SCARB2 processing and function. The accompanying website, explore-bridgead.com, enables users to trace the curated evidence and generate mechanistic hypotheses.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 21 Sep 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement